FDA Approves Pfizer Plan To Include Children As Young As 12 In COVID-19 Vaccine Study
- October 14, 2020
Reuters (10/13, Maddipatla, Burger) reports under a plan approved by the US Food and Drug Administration, Pfizer “will enroll participants as young as 12 in its large, late-stage COVID-19 vaccine trial to understand how it works in a wider age group.”
The New York Post (10/13, Manskar) reports that Pfizer, in a statement, said this “will allow researchers ‘to better understand the potential safety and efficacy of the vaccine in individuals from more ages and backgrounds.’”
CNN (10/13, Fox) also reports.